SGX To Focus On BCR-ABL Partnership After Discontinuing Troxatyl Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II/III trial in AML patients halted due to low response rates, but SGX says it will focus on a collaboration with Novartis.